

B-32 abstract named "Best of ASCO"

Dr. Thomas B. Julian's presentation at the 2013 ASCO meeting on long-term results from the NSABP B-32 trial has been named a "Best of ASCO" abstract and will be featured at Best of ASCO meetings here and abroad this summer. "Best of ASCO" presentations are considered to contain the most "high-impact and practice-changing" research results.

The abstract* summarizes findings from the National Surgical Adjuvant Breast and Bowel Project's study in women with breast cancer, which disclosed no significant overall or disease-free survival differences at 10 years between women with negative sentinel nodes who underwent SNR and those who underwent SNR plus axillary dissection. The researchers also found that the detection of occult tumor cells in the H&E-negative sentinel nodes offered no benefit.

Three Best of ASCO conferences will be held domestically in Chicago, Los Angeles, and Boston, and 25 will be held in other parts of the world including France, Egypt, Germany, Turkey, Saudi Arabia, and India. For more information about Best of ASCO meetings this year, go to <http://boa.asco.org/>

*Julian TB, Anderson SJ, Krag DN, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Wolmark N. "10-year follow up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients."